Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation

Livia Hegerova, Adam Bachan, Qing Cao, Huong X. Vu, John Rogosheske, Mark T Reding, Claudio G Brunstein, Mukta Arora, Celalettin Ustun, Gregory M Vercellotti, Veronika Bachanova

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Catheter-related thrombosis (CRT) occurs frequently during autologous hematopoietic cell transplantation (AHCT) and data regarding the incidence, risk factors, and management are understudied. We evaluated 789 consecutive patients with lymphoma and myeloma that underwent AHCT over 10 years (2006 to 2016) and detected the incidence of CRT was 6.3%; only 32% of CRT were symptomatic. The majority occurred within 100 days of AHCT (86%) and median time from tunneled line placement to CRT was 44 days (range, 11 to 89 days). Outcomes of these 50 patients with CRT were compared with age- and disease-matched AHCT control subjects to identify risk factors. History of prior venous thromboembolism (VTE) (20.9% versus 7.0%, P =.02) was the only significant risk factor. Treatment with low-molecular-weight heparin was tolerated with rare minor bleeding (4%), although CRT recurrence or extension (10%) and subsequent VTE (12%) were common. CRT did not impact on nonrelapse mortality or risk of relapse; 2-year progression-free survival was 55% in CRT cases versus 54% in control subjects (P =.42). CRT appears to be common in patients with lymphoma and myeloma undergoing AHCT and significantly contributes to morbidity. Further study to determine mitigating strategies and modify risk factors for CRT is warranted.

Original languageEnglish (US)
Pages (from-to)e20-e25
JournalBiology of Blood and Marrow Transplantation
Issue number12
StatePublished - Dec 2018

Bibliographical note

Publisher Copyright:
© 2018


  • Autologous transplantation
  • Catheter-related thrombosis
  • Lymphoma


Dive into the research topics of 'Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation'. Together they form a unique fingerprint.

Cite this